Allitinib tosylate

Allitinib tosylate (AST-1306 (TsOH) ) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib tosylate is an anilino-quinazoline compound and has anti-cancer activity[1]

Product Specifications

CAS Number

[1050500-29-2]

Product Name Alternative

AST-1306 (TsOH)

UNSPSC

12352005

Hazard Statement

H301, H311, H331, H341

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ast-1306-tsoh.html

Concentration

10mM

Purity

99.54

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC1=CC=CC(COC2=C(Cl)C=C(NC3=NC=NC4=C3C=C(NC(C=C)=O)C=C4)C=C2)=C1.O=S(C5=CC=C(C)C=C5)(O)=O

Molecular Formula

C31H26ClFN4O5S

Molecular Weight

621.08

Precautions

H301, H311, H331, H341

References & Citations

[1]Xie H, Lin L, Tong L et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6 (7) :e21487.